Patents by Inventor Thomayant Prueksaritanont

Thomayant Prueksaritanont has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AND RELATED USES
    Publication number: 20230391752
    Abstract: The present disclosure relates to compounds of Formula (I?): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for the treatment of a viral infection (e.g., hepatitis B virus or a Flaviviridae virus).
    Type: Application
    Filed: October 22, 2021
    Publication date: December 7, 2023
    Inventors: Tanachote RUENGSATRA, Eakkaphon RATTANANGKOOL, Pongkorn CHAIYAKUNVAT, Sirikan DEESIRI, Wilasinee DUNKOKSUNG, Udomsak UDOMNILOBOL, Natthaya CHUAYPEN, Pisit TANGKIJVANICH, Khanitha PUDHOM, Thomayant PRUEKSARITANONT
  • Screening and selection methods for statin drug combinations
    Patent number: 7407772
    Abstract: A method for screening statins in their open acid form to determine the susceptibility of each tested statin to metabolic glucuronidation is provided. Also provided is a method for determining if a non-statin pharmaceutical drug co-administered with a statin that is susceptible to metabolic glucuronidation in its open acid form, will inhibit the glucuronidation of the statin and thereby increase the risk of an adverse drug interaction.
    Type: Grant
    Filed: September 20, 2002
    Date of Patent: August 5, 2008
    Assignee: Merck & Co., Inc.
    Inventor: Thomayant Prueksaritanont
  • Alpha v integrin receptor antagonists
    Publication number: 20040254211
    Abstract: The present invention relates to novel compounds formed by metabolic conversion of compounds of structural formula (1), pharmaceutical compositions containing such compounds, and their use as &agr;v&bgr;3 integrin receptor antagonists. The compounds of the present invention are useful for inhibiting bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammatory arthritis, cancer, and metastatic tumor growth. They are particularly useful for inhibiting bone resorption and for the treatment and prevention of osteoporosis.
    Type: Application
    Filed: March 11, 2003
    Publication date: December 16, 2004
    Inventors: Byron H Arison, Donghui Cui, Mark E Duggan, Thomayant Prueksaritanont, Wasyl Halzczenko, Raju Subramanian, John H Hutchinson, Xiaojun Fang
  • Screening and selection methods for statin drug combinations
    Publication number: 20040180392
    Abstract: A method for screening statins in their open acid form to determine the susceptibility of each tested statin to metabolic glucuronidation is provided. Also provided is a method for determining if a non-statin pharmaceutical drug co-administered with a statin that is susceptible to metabolic glucuronidation in its open acid form, will inhibit the glucuronidation of the statin and thereby increase the risk of an adverse drug interaction.
    Type: Application
    Filed: March 23, 2004
    Publication date: September 16, 2004
    Inventor: Thomayant Prueksaritanont
  • &agr; v integrin receptor antagonists
    Patent number: 6426353
    Abstract: The present invention relates to novel compounds formed by metabolic conversion of compounds of structural formula (1), pharmaceutical compositions containing such compounds, and their use as &agr;v&bgr;3 integrin receptor antagonists. The compounds of the present invention are useful for inhibiting bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammatory arthritis, cancer, and metastatic tumor growth. They are particularly useful for inhibiting bone resorption and for the treatment and prevention of osteoporosis.
    Type: Grant
    Filed: September 14, 2001
    Date of Patent: July 30, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Byron H. Arison, Donghui Cui, Mark E. Duggan, Wasyl Halczenko, John H. Hutchinson, Thomayant Prueksaritanont, Raju Subramanian, Xiaojun Fang
  • Alpha v integrin receptor antagonists
    Publication number: 20020049224
    Abstract: The present invention relates to novel compounds formed by metabolic conversion of compounds of structural formula (1), pharmaceutical compositions containing such compounds, and their use as &agr;v&bgr;3 integrin receptor antagonists. The compounds of the present invention are useful for inhibiting bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammatory arthritis, cancer, and metastatic tumor growth. They are particularly useful for inhibiting bone resorption and for the treatment and prevention of osteoporosis.
    Type: Application
    Filed: September 14, 2001
    Publication date: April 25, 2002
    Inventors: Byron H. Arison, Donghui Cui, Mark E. Duggan, Wasyl Halczenko, John H. Hutchinson, Thomayant Prueksaritanont, Raju Subramanian, Xiaojun Fang
  • Alpha V integrin receptor antagonists
    Publication number: 20020040030
    Abstract: The present invention relates to novel compounds formed by metabolic conversion of compounds of the structural formula depicted below (R═H or Me), pharmaceutical compositions containing such compounds, and their use as &agr;v&bgr;3 integrin receptor antagonists. The compounds of the present invention are useful for inhibiting bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammatory arthritis, cancer, and metastatic tumor growth. They are particularly useful for inhibiting bone resorption and for the treatment and prevention of osteoporosis.
    Type: Application
    Filed: September 14, 2001
    Publication date: April 4, 2002
    Inventors: Paul J. Coleman, Donghui Cui, Mark E. Duggan, John H. Hutchinson, Thomayant Prueksaritanont, Maria Victoria Silva Elipe, Xiaojun Fang